11,611
Views
52
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer

, , , , , , , & show all
Pages 1669-1678 | Received 20 Nov 2017, Accepted 25 Jan 2018, Published online: 09 Feb 2018

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.